Film-coated tablets. A white to off white round, biconvex coated tablet with a breakline on one side and plain on the other side. The tablet can be divided into halves

Each film coated tablet contains: Active substance:

Pyrantel 80 mg (equivalent to 230 mg pyrantel embonate)

Praziquantel 20 mg

For the treatment of mixed infections caused by the following gastrointestinal roundworms and tapeworms:

Roundworms: Toxocara cati, Toxascaris leonina,

Tapeworms: Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis

To ensure administration of a correct dose, body weight should be determined as accurately as possible.

Dosage The recommended dose is: 20 mg/kg pyrantel (57.5 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.

Administration and duration of treatment

Single oral administration. The tablet should be given directly to the cat, but if necessary can be disguised in food.

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should, therefore, be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.

If signs of disease persist or appear, consult a veterinary surgeon.

Do not use simultaneously with piperazine compounds.

Do not use simultaneously with other deworming products without veterinary advice.

Do not use in kittens less than 6 weeks of age.

Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.

Do not use during pregnancy

Special warnings for each target species

Fleas serve as intermediate hosts for one common type of tapeworm – Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken. Development of parasite resistance to anthelmintics of a certain class can occur after frequent and repeated use of an anthelmintic from that class

i) Special precautions for use in animals

Not intended for use in cats weighing less than 1 kg bodyweight

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

In the interests of good hygiene, persons administering the tablets directly to the cat, or by adding them to the cat’s food, should wash their hands afterwards. In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.

Do not use during pregnancy but may be used during lactation

Do not use simultaneously with piperazine compounds.

Withdrawal period
Not applicable

After doses higher than 5 times the recommended dose, signs of intolerance such as vomiting have been observed.

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology) If the cat has visited areas where Echinococcus spp. are prevalent, a veterinarian should be consulted

Mild and short-lived digestive tract disorders such as excessive salivation and/or vomiting and mild and short-lived disorders of the nervous system such as loss of balance may occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)

- common (more than 1 but less than 10 animals in 100 animals)

- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)

- very rare (less than 1 animal in 10,000 animals, including isolated reports)

This veterinary medicinal product does not require any special temperature storage conditions Discard any unused half tablets immediately. Do not remove tablets from immediate packaging until require for use. Keep blister in the outer carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

The product is presented in either:

Individual blisters made up of a PVC/PE/PCTFE white opaque copolymer and a 20µm heatseal lacquer/aluminium containing 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 tablets.

or Individual blisters made up of 45µm PVC/aluminium/orientated polyamide and a 20µm heatseal lacquer/aluminium containing 2 or 4 tablets.

The blisters are packed into cartons containing either: 2 or 4 tablets.

Not all pack sizes may be marketed.

C&H Generics Ltd

c/o Michael McEvoy and Co Seville House New Dock Street Galway Ireland

Vm 40162/4008